Report Highlights
This report is designed to investigate recent years of performance of pharmaceutical and biopharmaceutical companies with respect to return on investment (ROI) in research and development (R&D), and to discuss ways that companies are trying to improve ROI through 2024. Investigation will include Country/Regional market trends with top areas of return, 2014-2024. This report also looks at which companies are already using artificial intelligence (AI) and machine learning (ML) to successfully compete globally.
Report Includes
- What are the major factors which have caused the decline in ROI in R&D for Pharma/Biotech?
- In what ways are new drug approvals affecting ROI?
- How can success rates in clinical development and testing be improved?
- How can tools such as Artificial Intelligence and Machine Learning, among others, decrease the costs of clinical trials?
- What is the digital transformation currently taking place, and how can companies deploy such tools?
Report Scope
The scope of this study begins with the challenges facing biotech and pharmaceutical companies today. It goes on to discuss regulatory approval processes in various countries, how these are changing, and the knock-on effects which the pharma/biotech companies will have to address. The report then reviews several key financial ratios, then discusses how to maximize clinical development success rate. We then go into how machine learning (ML) and artificial intelligence (AI), along with Big Data, are disrupting the pharma/biotech industry, in a positive way. The report then reviews the global markets for treatments for selected cancers, chronic diseases, cardiovascular disease, neurological diseases, infectious diseases and rare diseases. Chapter 15 discusses how companies need to deeply integrate ML, AI and Big Data into drug discovery and clinical testing—or risk falling behind the competition. The report wraps up with summaries of selected companies active in these spaces and beginning to utilize digital tools in R&D.
Analyst Credentials
Valerie Kellogg, RRT, BA, MS/MBA is an experienced medical device and pharmaceutical professional with international market research experience. She has authored numerous reports on topics ranging from the treatment of obesity to ablation devices, from wound care to the treatment of chronic migraine. Her strong focus areas include oncology, treatment of chronic disease, the latest in surgical devices and analysis of potential acquisitions.
Related Reports
Excipients in Pharmaceuticals: Global Markets to 2026
The global market for pharmaceutical excipients should grow from $8.3 billion in 2021 to $10.6 billion by 2026, at a compound annual growth rate (CAGR) of 5.0% for the period of 2021-2026.
Active Pharmaceutical Ingredients: Global Markets
The global market for active pharmaceutical ingredients (APIs) should grow from $135.4 billion in 2020 to $173.3 billion by 2025, at compound annual growth rate (CAGR) of 5.1% for the period of 2020-2025.
Medical Affairs: The Roadmap to 2025
This report on Medical Affairs highlights overall growth due to rapidly changing pharmaceutical and medical device markets by forming new paradigms and employing marketing strategies that increase market share. The research will provide information on leading market competitors, their market share, partnerships, collaborations, mergers and acquisitions between pharmaceutical companies. BCC Research focuses on the importance of medical affairs in communicating and collecting the medical evidence with the organization and external stakeholders.
Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry
This report provides information on significant drug launches in 2019. The study provides an overview of each drug, scientific summaries, pharmacodynamics, pharmacokinetics and clinical trial information, disease backgrounds, analysis of the market, competitors and company profiles of manufacturers. The objective of this study is to present a comprehensive analysis of the current market and its future direction.
Recent Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More